Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Journal of thrombosis and haemostasis : JTH - 1 Jan 2010

Ferder N S, Eby C S, Deych E, Harris J K, Ridker P M, Milligan P E, Goldhaber S Z, King C R, Giri T, McLeod H L, Glynn R J, Gage B F

Abstract excerpt

BACKGROUND: CYP2C9 and VKORC1 genotypes predict therapeutic warfarin dose at initiation of therapy; however, the predictive ability of genetic information after a week or longer is unknown. Experts have hypothesized that genotype becomes irrelevant once international normalized ratio (INR) values...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Vitamin K Epoxide Reductases
Share to Blood Coagulation
Share to Drug Dosage Calculations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to International Normalized Ratio

Share to Secondary Prevention

Share to Venous Thromboembolism

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 19874474
DOI: 10.1111/j.1538-7836.2009.03677.x
PMCID: PMC3718044

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19874474-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.PMID 19874474Read ↗

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Integration of genetic, clinical, and INR data to refine warfarin dosing.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Genetic determinants of response to warfarin during initial anticoagulation.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.Semantic proximity Read ↗

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.Semantic proximity Read ↗

Pharmacogenetics in warfarin therapySemantic proximity Read ↗

Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.